EXPLORE THE SCIENCE
The NLRP3 inflammasome is increasingly being recognized as a mediator between inflammation and depression. Targeting this molecular complex shows promise for developing new antidepressant therapies. Key Facts: The NLRP3 inflammasome is made up of NLRP3, ASC, a…
Read article
Researchers uncover a surprising molecular mechanism that explains ketamine’s exceptionally long-lasting antidepressant effects. Key Facts: Ketamine’s antidepressant effects last for days after its concentration drops to low, ineffective levels only an hour af…
Read article
Depression is one of the most common mental health issues, affecting over 320 million people globally. Research shows that exercise may be an effective treatment option for many battling this disabling condition. Key Facts: Exercise has comparable antidepressa…
Read article
Researchers conducted a comprehensive analysis comparing 20 antidepressants to identify the most effective options for preventing relapse in patients with major depressive disorder (MDD). Their findings suggest desvenlafaxine, paroxetine, venlafaxine and vorti…
Read article
Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybi…
Read article
New research finds that regular running is just as effective as antidepressants for treating depression and anxiety, and leads to better physical health outcomes. Key Facts: In a study of 141 patients, running therapy and antidepressant medication had comparab…
Read article
Depression affects over 300 million people globally. Current antidepressants have limited efficacy and slow onset of action. New research shows promise for compounds targeting metabotropic glutamate receptors 2 and 3 (mGluR2/3) as fast-acting antidepressants w…
Read article
New research reveals that increased inflammation, indicated by higher levels of a protein called VCAM-1, is associated with decreased gray matter and altered brain connectivity in patients with major depressive disorder (MDD). These brain changes also correlat…
Read article
A new study examined whether metabolic biomarkers assessed through a high-throughput method are associated with future depressive symptoms. The results suggest the metabolites may not play a direct role in depression development. Key Facts: Researchers investi…
Read article
A new meta-analysis found that continuous theta burst stimulation (cTBS), a novel form of brain stimulation therapy, does not appear to be more effective than sham (placebo) stimulation for treating symptoms of major depression. Key Facts: cTBS is a type of re…
Read article